Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

34.97 +0.13 (+0.37%)
Streaming Delayed Price Updated: 12:37 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Big Retailers Report
Good Morning Everyone! Customers are setting banks on fire in Lebanon because they can’t get their money out. Inflation is at +170%. This is what a currency collapse looks like: 
Via Benzinga
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
Alkermes Stock Sees Rising Relative Price Strength
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86. 
Via Investor's Business Daily
Anavex Life Sciences Stock Shows Improved Price Strength Rating
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75. 
Via Investor's Business Daily
With This Big Transition Ahead, Is Novavax a Buy?
Novavax stock sank 92% last year. 
Via The Motley Fool
4 Analysts Have This to Say About Harmony Biosciences
Within the last quarter, Harmony Biosciences (NASDAQ:HRMY) has observed the following analyst ratings: 
Via Benzinga
Where Harmony Biosciences Stands With Analysts
Analysts have provided the following ratings for Harmony Biosciences (NASDAQ:HRMY) within the last quarter: 
Via Benzinga
The 7 Best Biotech Stocks to Buy for February 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential. 
Via InvestorPlace
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. 
Via InvestorPlace
If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today
The stock has gone on a wild ride over the past few years. 
Via The Motley Fool
2 Biotechs Making Waves With A Single Product in their Pipeline
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise. 
Via MarketBeat
NVAX Stock Alert: What to Know as Novavax Names New CEO
Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries. 
Via InvestorPlace
6 Analysts Have This to Say About Harmony Biosciences
Harmony Biosciences (NASDAQ:HRMY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average. 
Via Investor's Business Daily
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
Looking Into Harmony Biosciences's Return On Capital Employed
According to Benzinga Pro, during Q3, Harmony Biosciences (NASDAQ:HRMY) earned $87.94 million, a 273.73% increase from the preceding quarter. Harmony Biosciences also posted a total of $117.21 million... 
Via Benzinga
Gartner, Sony, Uber And Other Big Gainers From Tuesday
U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2022 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Why IBD 50 Stock Harmony Biosciences Flew To The High End Of Its Buy Zone
The third-quarter beat, alone, wasn't enough to drive the positive stock movement. 
Via Investor's Business Daily
Recap: Harmony Biosciences Q3 Earnings
Harmony Biosciences (NASDAQ:HRMY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Harmony Biosciences... 
Via Benzinga
Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
Upgrades 
Via Benzinga
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.26... 
Via Benzinga
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
  
Via Benzinga
Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat
Shares surged well above the 5% chase zone in early action Tuesday. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback